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ABSTRACT
Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more 
efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well 
and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the 
reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on 
serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A 
total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for 
JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. 
The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were 
similar to those described in other countries.
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The John Cunningham virus ( JCV) is a ubiquitous poly-
oma virus that exclusively infects humans1. Primary expo-
sure to the JCV is asymptomatic, usually occurring during 
childhood or adolescence, although the development of anti-
JCV antibodies may also occur later in life2. The JCV can be 
found in a latent state in several tissues, including the brain3, 
where it can cause progressive multifocal leukoencephalopa-
thy (PML) in immunosuppressed patients4. 
The advent of very potent monoclonal antibody immunolog-
ical treatments for multiple sclerosis (MS) brought about a new 
category of patients at risk for PML5. Whereas, previously, PML 
was almost exclusively in patients suffering from severe immu-
nosuppression ( for example, patients with AIDS), now individ-
uals with MS treated with natalizumab require monitoring of 
their JCV serum status and proper management of drug with-
drawal if necessary6,7. The risk of developing PML in MS cases can 
be stratified, and patients at higher risk may go straight to other 
therapeutic options or have shorter-term treatment with natali-
zumab5. In the absence of an effective treatment for a devastating 
disease like PML, patients with MS undergoing treatment with 
newer drugs must be closely monitored in order to minimize 
central nervous system injury and to avoid severe disability6.
It is essential to ascertain the overall prevalence of the 
JCV in patients with MS, in order to make better use of rec-
ommendations and guidelines regarding the risk of PML. 
The proportion of the adult population with antibodies for 
the JCV seems to vary between 50% and 90%8. A previous 
Brazilian study found that 51.2% out of 168 patients with MS 
were seropositive for the JCV9. The objective of the present 
study was to assess a much larger Brazilian population of 
patients with MS regarding seropositivity for the JCV.
METHODS
This study was approved by the Ethics Committee of 
Universidade Metropolitana de Santos under the number 
CAAE 05669912.3.0000.5509. Additional approval from other 
MS centers was obtained, whenever necessary, by the par-
ticipating neurologists. 
Serum antibodies for the JCV were detected using the 
enzyme-linked immunosorbent assay. This test was always 
performed by the same laboratory and was done in accordance 
with the STRATIFY-JCV program (Biogen Idec, Cambridge, 
MA, USA). The results were analyzed in a descriptive manner 
and were presented as median values. Fisher’s exact test and 
Pearson’s correlation were assessed using SPSS 24.0 software.
RESULTS
A total of 1,501 blood tests were obtained from 1,102 
patients with MS over five years (2012 to 2017). There were 
793 women and 314 men (2.5:1); and the patients’ median 
age was 38 years. The patients underwent a variety of thera-
pies and not all of them used (or had previously used) natali-
zumab for MS control.
In a cross-sectional analysis in October 2017, 633 patients 
(57.1%) were found to be positive for antibodies for the 
JCV and 469 patients were negative (42.9%). Twenty-three 
patients became positive after initially having negative JCV 
antibody status. Therefore, at the beginning of the assessment 
(2012), there were 610 JCV-positive patients (55.3%) and 592 
patients who had tested negative at least once (54.7%). Men 
were significantly more prone to having a JCV-positive status 
(p < 0.001), while age did not influence results (r = 0.115). 
Taking into consideration the 124 seronegative patients who 
had had more than one JCV test, seroconversion occurred in 23 
cases (18.5%) over a median period of 22 months. Seroconversion 
was not associated with the patient’s age or sex. Because the 
number of patients who were negative for the JCV and con-
verted to positive was small (n = 23), it was not possible to con-
duct further analysis on all factors that might potentially affect 
seroconversion ( for example, previous therapies). 
DISCUSSION
The rate of seropositivity for anti-JCV antibodies in the 
Brazilian population of patients with MS seems to have 
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remained stable in relation to a previous study published 
five years ago9. The cross-sectional prevalence of Brazilian 
JCV-seropositive patients with MS increased from 51.8% (n 
= 186) in 2012–2013 to 57.1% (n = 1,102). This difference was 
not significant (p = 0.09), and these prevalence values are in 
line with those reported by other authors10,11. A recent review 
of the worldwide prevalence of the JCV in patients with MS 
and neuromyelitis optica included data from 26 countries11. 
The median prevalence around the world was the same as 
in the present Brazilian study (57.1%) and the range of posi-
tive results for JCV antibodies was 40% to 69%11. The fact that 
data on this subject are now being analyzed and reported in 
so many countries emphasizes the importance of this matter.
The rate of JCV seroconversion in Brazilian patients 
with MS is similar to that reported in other countries. 
Seroconversion occurred in 15.9% of the patients over a 
period of 14.8 months12, in 14.5% after 12 months13, 17.6% over 
18 months14 and 26.7% over an average period of 43 months15. 
In a recently published review of data in the literature, which 
included two large cohort studies, the seroconversion rate 
per year was 10.8%16. On the other hand, other researchers 
have described much lower seroconversion rates: for exam-
ple, in only 5.8% of the patients in Portugal after five years17. 
Regarding the correlation between natalizumab use and 
seroconversion, it has been shown that the serum levels of 
natalizumab were not associated with the JCV antibody sta-
tus, JCV antibody index or seroconversion18. Other authors 
have reported different results and have correlated use of 
natalizumab with seroconversion to JCV19. In fact, a recent 
longitudinal study showed seroconversion to be 11.5%, but 
there were also high numbers of intermittently seropositive 
cases (9.7%) and seroreverters (3.6%)20. The JCV serostatus 
stability was not influenced by age, sex, disease duration or 
number of natalizumab infusions20. The predictive factor 
for JCV stability was the baseline anti-JCV antibody index21. 
When the index was higher than 0.9, it predicted stable posi-
tive serostatus (sensitivity 88.7%, specificity 96.5%), and when 
it was lower than 0.2, it predicted stable negative serostatus 
(sensitivity 61.3%, specificity 97.6%)21.
The present study did not assess serum levels of natali-
zumab nor did it obtain detailed data regarding its use as 
therapy for MS. The potential influence of MS treatments on 
seroconversion was not considered in the present analyses 
and will be addressed in further (and larger) population stud-
ies. Likewise, the serum index of anti-JCV antibodies will be 
assessed from now on by the Brazilian group as a potential 
predictive factor for JCV serostatus stability. These were limi-
tations to our study as a small number of seroconverters were 
identified, and these could not be studied in further detail.
In conclusion, seropositivity for and seroconversion to 
JCV in Brazilian patients are similar to those described in 
other countries. The high number of epidemiological studies 
similar to ours reinforces the concerns regarding the matter 
of the JCV, PML and MS.
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